Proudly announcing that Akums Drugs & Pharmaceuticals has secured a patent for its dual-action nausea drug for pregnant women. This breakthrough offers enhanced relief from morning sickness, improving comfort during early pregnancy.

Mr. Sanjeev Jain, MD of Akums, has been honoured with the Times Business Award 2025 for Outstanding Contribution to the Pharmaceutical Industry. The award marks a testament to his unwavering dedication and impact in the pharma space.

Ms. Arushi Jain, Director – Growth and Strategy at Akums, shares her insights in Pharma Bio World on the future of CDMOs in India. She highlights key opportunities shaping the country’s pharmaceutical landscape.

In collaboration with Tamil Nadu Agricultural University, Akums will advance research in pharma formulations using sustainable, agri-based inputs. The focus lies on plant-derived innovations for pharma and nutraceuticals.

Honoured to receive the Excellence in Manufacturing – Healthcare & Pharmaceuticals (Large Scale) award at the ET Entrepreneur Summit & Awards. Grateful for the recognition that inspires our commitment to quality and care.

Proud moment as our Director, Sh. Sanjeev Jain, is recognised at TIMES POWER ICONS North 2024-25 for Excellence in Pharmaceuticals. His leadership continues to drive innovation and growth at Akums.

Recognized at the Healthcare Heroes Summit & Awards, Team Akums is proud to receive the Editor’s Choice award for Game Changers in Disease Diagnosis. Our Hydroxyurea Oral Suspension for Sickle Cell Disease reflects our dedication to advancing meaningful healthcare innovations.

On Akums' 21st anniversary, we celebrated with gratitude and reflection, honouring our journey, our people, and the shared purpose that drives us. Here's to fostering continued growth and embracing future opportunities.

Proud moment for Akums as Sh. Sanjeev Jain, MD, Akums, is recognized among the Global 200 Inspirational Leaders 2025. His vision has redefined contract manufacturing, making Akums India’s largest pharmaceutical contract manufacturer.

Recognized as a People’s Choice Company to Work at the National Economic Growth Summit by Talent Value Media. Grateful to be part of a platform that champions growth, leadership, and excellence.

Proud to receive three prestigious recognitions at the Financial Express Pharma Summit & Awards. These honors inspire us to drive research, innovation, and India's pharmaceutical growth. Grateful to our team and partners for their support.

Arushi Jain has been recognized at ET Women Conclave 2025 for her leadership in driving change and breaking barriers. At Akums, we remain committed to empowering women and fostering an inclusive, thriving workplace.

Arushi Jain, Director at Akums, shares in Express Pharma how women in leadership drive innovation and business success. She advocates for greater diversity in management to build stronger, more inclusive workplaces.

Akums is honored to be recognized as the 'Most Preferred Workplace' at the HDM Awards 2024 for our commitment to integrity, inclusivity, and innovation.

Honored to receive the "Pharma Company of the Year" at the ET Re-Pharma Awards, recognizing innovation and excellence in healthcare.

Akums launches Dapagliflozin-Pioglitazone tablets, a dual-action therapy for better type 2 diabetes management and improved glycemic control.

Akums' CSR initiative empowers physically disabled individuals with assistive devices, fostering independence and inclusivity.

Akums launches a state-of-the-art facility for lyophilized products, enhancing sterile manufacturing across injectables, vials, FFS, and eye/ear drops.

Honored to win ET RePharma Awards 2025 for ‘Excellence in Formulations’ (3rd year) & ‘Pharma Contract Services – Manufacturing’ (2nd time), reaffirming our commitment to innovation and quality.

Akums Drugs has partnered with Jagdale Industries for the marketing and distribution of ready-to-drink nutritional beverages, expanding its portfolio in the health and wellness segment.

Akums has partnered with Caregen to introduce an innovative range of nutraceuticals and cosmeceuticals in India, aiming to revolutionize health and skincare solutions in the market.

Earning a spot among the Top 200 Companies with Global Business Potential underscores a strong commitment to excellence, remarkable growth, and a significant impact on international markets.

Akums has been honored with the prestigious award for “Most Trusted Pharmaceuticals Brand - Delhi,” recognizing its commitment to quality, innovation, and customer trust.

Akums has been recognized as an Innovator in Manufacturing, receiving the prestigious Certificate of Recognition at the renowned Elets Healthcare Innovation Awards 2024 for its outstanding achievements.

Akums received the prestigious 'Pharmaceutical Supply Chain Shakti' award at the Logistics Shakti Summit & Awards, recognizing its excellence in supply chain management and operational efficiency.

We are delighted to share that Akums has been honored with the Sustainable Organization Award 2024 at the 4th Sustainable Summit & Awards by UBS Forums in Bengaluru! Grateful for the recognition of our commitment to building a sustainable future in healthcare!

Stellar debut on the stock exchanges, closing 17.23% above the IPO price, reflecting strong investor confidence with the issue being subscribed 63.56 times. The robust listing marks a significant milestone in Akums' journey of growth and industry leadership.

Akums has introduced new formulations specifically for gastrointestinal patients in India. These innovative treatments aim to enhance patient care and address various gastrointestinal issues effectively.

Akums has unveiled a new generic formulation for migraine treatment, offering an innovative and cost-effective option for patients. This launch highlights Akums' commitment to addressing the needs of those suffering from chronic migraines.

The Hydroxyurea Oral Suspension will be used for the symptomatic management of sickle cell syndrome, aiming to prevent recurrent painful vaso-occlusive crises, including acute chest syndrome, in adults, adolescents, and children over 2 years old.

Akums has introduced a new DCGI-approved medication for treating resistant hypertension. This fixed-dose combination of Amlodipine, Telmisartan, and Metoprolol aims to improve patient compliance and enhance long-term blood pressure control.

Akums proudly unveils its 20th Anniversary Campaign, 'BHAROSA – Two Decades of Trust, Going Strong', celebrating a legacy of reliability, sustainability, and innovation in pharmaceutical manufacturing.

Akums ventures into nasal sprays, offering a globally recognized dosage form known for convenience, enhanced compliance, and rapid onset of action. From respiratory to neurology and analgesics, explore the diverse therapeutic applications for both local and systemic relief.

Kanishk Jain of Akums Drugs and Pharmaceuticals has been appointed as the Chairman of the Confederation of Indian Industry (CII) Uttarakhand State Council for the 2024-25 term.

Akums takes a bold step towards organ donation awareness, dedicating efforts to educate and engage the community in building a healthier and more compassionate society

Inception Day festivities that took place at Akums' office. The occasion was marked with great enthusiasm and excitement as everyone came together to commemorate the anniversary.

Akums awarded as the "Most Admired Quality Pharmaceutical Manufacturer of Indian 2023" by Super30 Healthcare presented by Observe Now.

Akums Drugs and Pharmaceuticals Ltd. has been honored with the prestigious "Dream Employer of the Year" award by Times Ascent . It gives immense pleasure to convey heartiest congratulations to the entire team of Akums for this remarkable achievement.

Akums got felicitated with the Exchange4media award on 19th Jan 2023. The award recognizes and celebrates the best brands based in North India.